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Background
Primate innate immune mechanisms are critical for the
normal development of adaptive immune responses to
antigen.  Part of the modern effort to design and distribute
vaccines against pathogens must involve detailed descrip-
tions of innate responses resulting from vaccine chal-
lenges.  Particularly, the interaction between Natural
Killer (NK) and Dendritic cells is expected to greatly
impact the establishment of both innate and adaptive
immune responses to vaccine.  In this study, we describe
responses of Natural Killer cells to recombinant Modified
Vaccinia Virus Ankara expressing HIV-1 genes (rMVA)
compared to wild type MVA (MVAwt).
Methods
We employed an autologous in vitro NK/DC co-culture
system to explore the interaction between MVA-infected
DC and Natural Killer cells.
Results
Using a fluorescent dye system, we show that MVA
infected DC are phagocytosed by uninfected DC after 48h
in co-culture.  We also demonstrate that NK cells stimu-
lated in co-culture with MVA-infected DC proliferate
when compared to the uninfected DC stimulation;
though no difference in proliferation kinetics could be
identified between recombinant MVA (rMVA) and wild
type MVA (MVAwt) stimulated NK.  Both MVA strains
were capable of inducing NK repertoire differentiation but
comparative analysis demonstrated that NK stimulated
with rMVA specifically expressed higher levels of CD158e
and NKG2D than NK in the MVAwt condition.  Finally,
using HIV-GFP or HIV-Bal5 strains, we show that NK cells
stimulated by rMVA are better at controlling HIV infection
in vitro than NK stimulated by MVAwt.
Conclusion
These data demonstrate that innate responses to this
rMVA vaccine against HIV can be detected in vitro and
that this response results in the establishment of “acti-
vated/memory” Natural Killer cells capable of controlling
HIV replication and infection.  Future experiments will
identify the specific molecular mechanisms responsible
for the DC-mediated activation of NK, as well as the NK-
dependent control of HIV infection.
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